You are here



Treatment type:

Code name: 
Commercial name: 
Treatment line: 
  • Second line
  • Third line
  • Fourth line
  • Fifth line

Ponatinib (Iclusig, Incyte Corporation) is a third generation TKI (tyrosine kinase inhibitor) used as an option for the treatment of chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) in patients that are resistant to, or intolerant of, dasatinib or nilotinib, or who have the T315i mutation and for those whose subsequent treatment with imatinib is not clinically appropriate . Prescribed in once‑daily oral doses of 15 mg, 30 mg or 45 mg dose levels and dose adjustments are determined by time on treatment, treatment response and adverse reactions. Ponatinib inhibits many mutated forms, including the multi-drug resistant T315i mutation. Evidence has emerged that ponatinib is associated with an increased risk of arterial occlusion. In the ponatinib PACE trial (Ph+ ALL and Ph+CML) the incidence of arterial occlusion in patients treated with 45mg daily, was 19% by 12 months with an increased risk of 29% by 24 months. In order to minimise these risks, patients should be carefully evaluated for their cardiovascular status prior to ponatinib initiation with adequate prevention measures set in place to reduce risk.

Available in England and the devolved NHS administrations as a routine treatment for its licensed indications
Available for routine treatment within the licensed indication
Available for routine treatment within the licensed indication
Northern Ireland
Available for routine treatment within the licensed indication
type: Clinical trial
published: 15 November 2015
type: Event
published: 6 November 2015
type: Clinical trial
published: 28 June 2015